UnknownPhase 4

Impact of Dexmedetomidine on Acute Kidney Injury Following Living Donor Liver Transplantation

South Korea214 participantsStarted 2017-07-11

Plain-language summary

Acute kidney injury (AKI) following liver transplantation (LT) is associated with increased costs, morbidity, and mortality. Dexmedetomidine has known to have anti-inflammatory effect and has been shown to ameliorate IRI in several organs. However, the impact of Dexmedetomidine on AKI after LT is not determined yet. Therefore, this study aims to observe the renal protective effects of Dexmedetomidine after LT.

Who can participate

Age range20 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * living liver transplantation recipients Exclusion Criteria: * preoperative renal dysfunction * dual living donor liver transplantation * severe cerebral artery disease * severe cardio-pulmonary disease

What they're measuring

acute kidney injury

Timeframe: 7 days

Trial details

NCT IDNCT03522688

SponsorAsan Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-07-14

View on ClinicalTrials.gov More Acute Kidney Injury trials